IKT

1.3201.54%
DJ

David John McIntyre

Chief Financial Officer

Mr. David John McIntyre, B.EC., CPA, LL.B., MBA, B.Econs (Acc), is Chief Financial Officer of Inhibikase Therapeutics, Inc. from April 14, 2025. Mr. McIntyre was Chief Financial Officer at Anthos Therapeutics, Inc. since January 2022 and joined the company in January 2022. Mr. McIntyre has global financial, operational and legal experience. He served as a Non-Executive Director at Starpharma Holdings Limited since 2023 and had been its Independent Non-Executive Director since March 01, 2020 until 2023 and also serves as it's Independent Non Executive Director. Mr. McIntyre served as Chief Financial Officer at AVITA Therapeutics, Inc. (formerly known as Avita Medical Limited) from November 18, 2019 to November 23, 2020 and also CFO at AVITA Medical, Inc. (NASDAQ: RCEL), a regenerative medicine company, from October 2021 to October 2024, October 2020 to October 2021, November 2019 to November 2020, respectively. He served as Chief Financial Officer, Executive Vice President and Treasurer at Braeburn Pharmaceuticals, Inc. since October 2016. Mr. McIntyre served as a Partner at Apple Tree Partners. He was responsible for Apple Tree Partners medical device portfolio, together with various operating and Board functions, including Acting as Executive Vice President, Chief Financial Officer and Head of Technical Operations at Braeburn, Inc. He has executive experience in the life science sector. His experience covers all key areas described in the Board skills matrix. In particular, he has substantial expertise in accounting/corporate finance, audit and risk; M&A/capital markets; governance; licensing and commercialisation of innovation; strategy and risk management. He has also had significant experience with US based companies in the medical device, biotechnology and pharmaceutical sector. Mr. McIntyre served as the Chief Financial Officer of HeartWare Inc. from February 2005 to December 2011 and served as its Chief Operating Officer since December 5, 2008. He served as a Principal Accounting Officer and Executive Vice President of HeartWare, Inc. He served as the Chief Financial Officer and Secretary of Heartware International Inc. from February 2005 to 2011 and also served as its Chief Operating Officer since 2008 until 2011 where he oversaw its financial, supply chain and operating functions. Mr. McIntyre served as the Chief Business Officer of Heartware International Inc. since August 2008. He served as Principal Accounting Officer and Executive Vice President at Heartware International Inc., since 2005 until 2011. He served as a Company Secretary of Heartware Inc. from February 2005 to December 5, 2008 and Chief Business Officer from August 2008 to December 5, 2008. He served as Chief Financial Officer and Executive Vice President at Tessa Therapeutics Pte Ltd until, 2021. He served as Principal Accounting Officer of HeartWare Ltd. Prior to HeartWare. Mr. McIntyre practiced as a senior attorney in private practice specializing in corporate law, mergers and acquisitions and equity capital markets with Baker & McKenzie and KPMG as well as holding various senior financial roles in multi-national companies, including within the Rio Tinto Group of companies. With professional qualifications in finance and law. Mr. McIntyre has held senior financial, legal and operational roles. From November 2003 to February 2005, he served as the Chief Financial Officer and General Counsel of Unilife Medical Solutions Limited. He was also in private practice as a Senior Attorney of KPMG Legal from May 2003 to October 2003 and Legal and Business Affairs Manager of Bulldogs League Club Limited from November 2001 to April 2003. He held senior financial reporting roles in multinational companies, among them Coal & Allied Limited. He has been a Director of VytronUS, Inc. since October 29, 2014. He has been a Director of ROX Medical, Inc., since September 6, 2016. He has been a Non-Executive Director of Redflex Holdings Limited since March 13, 2015. He serves as a Director of QualDerm, Advanced ENT Solutions, Inc. (formerly known as Tusker Medical, Inc.) and Gala Therapeutics. He has also served as Inside Director of Braeburn Pharmaceuticals since January 2016. He served as Director of Tendyne Holdings Inc., since April 10, 2014. He served as Director of Avedro, Inc. since March 27, 2015. He has extensive experience as a Senior Executive and Corporate Advisor with multinational and growth companies in a wide variety of industries, including medical devices. He is a Certified Practicing Accountant Australia (CPA). He is also admitted as a solicitor and legal practitioner of the Supreme Court of New South Wales and of the High Court of Australia. Mr. McIntyre holds a Bachelor of Economics (Accounting) from the University of Sydney, Australia, a Bachelor of Laws from the University of Technology, Sydney and an MBA from Duke University Fuqua School of Business (Fuqua Scholar) from Durham, North Carolina, in the United States of America.

Positions